Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note published on Tuesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

NASDAQ EVOK opened at $4.04 on Tuesday. The firm has a market capitalization of $6.00 million, a P/E ratio of -0.37 and a beta of 0.16. Evoke Pharma has a 1-year low of $3.44 and a 1-year high of $12.32. The business’s 50-day simple moving average is $4.63 and its 200-day simple moving average is $4.75.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC lifted its stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 148,194 shares of the specialty pharmaceutical company’s stock after buying an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned 9.95% of Evoke Pharma worth $655,000 as of its most recent filing with the SEC.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.